WO2006001122A1 - Rnaウイルスが導入された樹状細胞を含む抗癌剤 - Google Patents
Rnaウイルスが導入された樹状細胞を含む抗癌剤 Download PDFInfo
- Publication number
- WO2006001122A1 WO2006001122A1 PCT/JP2005/008175 JP2005008175W WO2006001122A1 WO 2006001122 A1 WO2006001122 A1 WO 2006001122A1 JP 2005008175 W JP2005008175 W JP 2005008175W WO 2006001122 A1 WO2006001122 A1 WO 2006001122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- virus
- rod
- cell
- rna
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 34
- 241000700605 Viruses Species 0.000 title claims description 109
- 210000004443 dendritic cell Anatomy 0.000 title abstract description 27
- 241001493065 dsRNA viruses Species 0.000 claims abstract description 169
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 105
- 208000015181 infectious disease Diseases 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 239000002245 particle Substances 0.000 claims description 28
- 230000010076 replication Effects 0.000 claims description 23
- 230000002458 infectious effect Effects 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 108091008794 FGF receptors Proteins 0.000 claims description 14
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 13
- 108090000467 Interferon-beta Proteins 0.000 claims description 7
- 102100026720 Interferon beta Human genes 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 469
- 239000005090 green fluorescent protein Substances 0.000 description 61
- 210000001744 T-lymphocyte Anatomy 0.000 description 56
- 108091007433 antigens Proteins 0.000 description 53
- 102000036639 antigens Human genes 0.000 description 51
- 239000000427 antigen Substances 0.000 description 50
- 230000000694 effects Effects 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
- 108090000765 processed proteins & peptides Proteins 0.000 description 35
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 32
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 32
- 239000002158 endotoxin Substances 0.000 description 32
- 229920006008 lipopolysaccharide Polymers 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 238000011282 treatment Methods 0.000 description 24
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 22
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 21
- 108010081734 Ribonucleoproteins Proteins 0.000 description 19
- 102000004389 Ribonucleoproteins Human genes 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 108090000978 Interleukin-4 Proteins 0.000 description 17
- 102000004388 Interleukin-4 Human genes 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 16
- 210000001616 monocyte Anatomy 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 241000711408 Murine respirovirus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 230000000242 pagocytic effect Effects 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 101710085938 Matrix protein Proteins 0.000 description 12
- 101710127721 Membrane protein Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 11
- 108010067390 Viral Proteins Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 10
- 241000712079 Measles morbillivirus Species 0.000 description 10
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 10
- 230000000139 costimulatory effect Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102100035793 CD83 antigen Human genes 0.000 description 8
- 101710091045 Envelope protein Proteins 0.000 description 8
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 8
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
- 102100020880 Kit ligand Human genes 0.000 description 8
- 101710181008 P protein Proteins 0.000 description 8
- 101710177166 Phosphoprotein Proteins 0.000 description 8
- 101710188315 Protein X Proteins 0.000 description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000005486 microgravity Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 230000024245 cell differentiation Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 210000004700 fetal blood Anatomy 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 241000712083 Canine morbillivirus Species 0.000 description 6
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 6
- 241000712041 Human parainfluenza virus 4a Species 0.000 description 6
- 241000712036 Human parainfluenza virus 4b Species 0.000 description 6
- 241000726041 Human respirovirus 1 Species 0.000 description 6
- 241001559187 Human rubulavirus 2 Species 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 241000711899 Phocine morbillivirus Species 0.000 description 6
- 241000711897 Rinderpest morbillivirus Species 0.000 description 6
- 241001428894 Small ruminant morbillivirus Species 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 241000712003 Human respirovirus 3 Species 0.000 description 5
- 241000711386 Mumps virus Species 0.000 description 5
- 102100034574 P protein Human genes 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000711404 Avian avulavirus 1 Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 101710198474 Spike protein Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- -1 cytosites Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 3
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 3
- 241001481833 Coryphaena hippurus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 241000893570 Hendra henipavirus Species 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 3
- 241000526636 Nipah henipavirus Species 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000000316 virotherapy Methods 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 101150034814 F gene Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 101150008820 HN gene Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 101150062031 L gene Proteins 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 101900194079 Sendai virus Matrix protein Proteins 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 208000017563 cutaneous Paget disease Diseases 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000007697 B7-2 Antigen Human genes 0.000 description 1
- 108010021800 B7-2 Antigen Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710112622 C-C motif chemokine 19 Proteins 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010082161 Chemokine CCL19 Proteins 0.000 description 1
- 102000003805 Chemokine CCL19 Human genes 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102220599936 Disks large-associated protein 5_G69E_mutation Human genes 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010067807 Gingival cancer Diseases 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101100519721 Homo sapiens PDGFRB gene Proteins 0.000 description 1
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108060004056 Integrin alpha Chain Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000896974 Mus musculus C-C motif chemokine 21a Proteins 0.000 description 1
- 101000896969 Mus musculus C-C motif chemokine 21b Proteins 0.000 description 1
- 101000896970 Mus musculus C-C motif chemokine 21c Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 208000009341 RNA Virus Infections Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 102100032743 Septin-4 Human genes 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000017777 integrin alpha chain Human genes 0.000 description 1
- 210000001911 interdigitating cell Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 201000009023 maxillary cancer Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010042234 peptide SVYDFFVWL Proteins 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464408—Platelet-derived growth factor receptors [PDGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18832—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18871—Demonstrated in vivo effect
Definitions
- the present invention relates to the field of cancer therapy.
- Viral therapy is a treatment that cures tumors by infecting tumor cells with proliferating viruses such as HSV-1 and adenovirus, and killing the virus by the virus-killing effect associated with virus growth.
- proliferating viruses such as HSV-1 and adenovirus
- the proliferating virus for tumor treatment is a mutant virus in which the virus genome has been genetically engineered, and has minimal pathogenicity in normal human tissues while maintaining replication in the tumor. It is held to the limit.
- the therapeutic propagating virus that infects tumor cells replicates within the cell, and in the process, the infected cell dies. The propagated virus re-infects surrounding tumor cells and spreads antitumor effects (Alemany R. et al "Replicative adenoviruses for cancer therapy. Nat Biotechnol., 2000,
- Viral therapy for cancer can be used in combination with conventional therapies such as surgery 'radiotherapy' chemotherapy, can be applied to solid cancer in general, it can be administered repeatedly, cytokines, etc.
- the therapeutic range can be directly integrated into the viral genome to enhance the anti-tumor effect, which is excellent in practical applications with a wide range of applications. If more effective viral therapies can be developed, it is expected to contribute greatly to cancer treatment.
- Non-patent document 1 Alemany R. et ai., Replicative adenoviruses for cancer therapy. Nat Biotechnol, 2000, 18: 723-727
- Non-Patent Document 2 Curiel, DT, The development of conditionally replicative adenoviruses for cancer therapy., Clin Cancer Res., 2000, 6: 3395—9
- Non-specialized literature 3 Kirn, D., Virotherapy for cancer: Current status, hurdles, and future directions., Cancer Gene Therapy, 2002, 9 : 959—960
- the present invention provides an anticancer agent comprising a rod-like cell into which an RNA virus has been introduced.
- the present invention also provides a method for producing an anticancer agent, comprising the step of producing rod-shaped cells into which an RNA virus has been introduced.
- the present invention also provides a method for treating cancer using rod cells into which an RNA virus has been introduced.
- RNA virus having genome replication ability when introduced into a rod-shaped cell, the rod-shaped cell is activated and exhibits an excellent anticancer effect.
- the suppressive effect on cancer growth when RNA virus was injected into cancer via rod cells was significantly higher than that of direct injection of RNA virus into cancer. Since the process of introducing RNA virus into rod cells can be performed outside the body, it is possible to strictly control the conditions for virus introduction compared to conventional virus therapy, and the ability to infect rod cells It is also possible to improve safety by removing viruses.
- the anticancer effect of the rod-shaped cells into which the RNA virus was introduced was also observed when a defective virus that did not release infectious virus particles was used.
- RNA virus the antitumor effect of rod cells introduced with RNA virus is important for RNA viruses to replicate genomic RNA in the rod cells, releasing infectious virus particles and infecting surrounding cells. There is no need to expand. Therefore, using highly safe RNA viruses that have lost the ability to form infectious virus particles by deleting the virus genes that encode proteins essential for the formation of infectious virus particles, such as viral envelope proteins. Viral therapy can also be performed.
- the present invention relates to an anticancer agent comprising a rod-like cell into which an RNA virus has been introduced, a method for producing the anticancer agent, and a method for suppressing cancer using a rod-like cell into which an RNA virus has been introduced. More specifically, the present invention relates to the invention described in each claim. It should be noted that one or more inventions that combine the inventions recited in the claims that refer to the same claim are already intended for expression in those claims. That is, the present invention
- an anticancer agent comprising a rod-shaped cell into which an RNA virus having genome replication ability has been introduced
- RNA virus is an infectious or non-infectious virus particle
- RNA virus is a genomic RNA-protein complex
- a method for producing an anticancer agent comprising a step of introducing an RNA virus having genome replication ability into a rod-shaped cell
- a method for suppressing cancer comprising a step of administering rod cells into which an RNA virus having genome replication ability has been introduced.
- FIG. 1 is a diagram showing a phenotype of a rod-shaped cell derived from a mononuclear cell of a peripheral blood monocyte-enriched cell. Gate the live cells identified by sputum, and use CD11c and HLA-class II (DR, DP) using anti-CD11c-competent antibody and anti-HLA-class II (DR, DP, DQ) FITC-conjugated antibody. , DQ) was observed (left matrix).
- select gates that are positive for both CDllc and HLA-class II were used to show the expression level of each in a dot plot with CDllc (three matrices on the right).
- ⁇ Class ⁇ is the result of using an antibody that recognizes all of HLA-DR, DQ, and DP
- HLA-DR ⁇ is the result of using an antibody that specifically recognizes HLA-DR. Represents.
- FIG. 3 is a graph showing the efficiency of introduction of GFP-expressing RNA virus into human monocyte-derived rod cells and the activity of rod cells (second day after infection).
- FIG. 4 A graph showing the efficiency of introduction of GFP-expressing RNA virus into human monocyte-derived rod cells and the activity of rod cells (4 days after infection).
- FIG. 5 is a graph showing the efficiency of introduction of GFP-expressing RNA virus into human monocyte-derived rod cells and the activity of rod cells (8 days after infection).
- FIG. 6 is a graph showing changes in the number of DCs after introduction of a GFP-expressing RNA virus.
- FIG. 7 is a diagram showing the GFP expression period after GFP expression RNA virus introduction.
- FIG. 8 is a graph showing the effect of LPS stimulation on the efficiency of introducing GFP-expressing RNA virus into human DCs.
- FIG. 9 is a graph showing the effect of LPS stimulation on the efficiency of introducing GFP-expressing RNA virus into human DCs.
- FIG. 10 is a diagram showing the results of examining the incubation time for gene transfer into DC.
- FIG. 11 is a diagram showing gene transfer into cord blood-derived DC.
- FIG. 12 is a diagram showing gene transfer into cord blood-derived DC.
- FIG. 13 shows the expression of costimulatory molecules after gene introduction (comparison with LPS stimulation).
- FIG. 14 shows the expression of costimulatory molecules after gene introduction (comparison with LPS stimulation).
- FIG. 15 shows the expression of costimulatory molecules after gene introduction (comparison with LPS stimulation).
- FIG. 18 is a diagram showing cytodynamic in production of monocyte-derived DC after introduction of RNA virus.
- FIG. 19 shows the expression of marker protein on rod cells after introduction of RNA virus.
- FIG. 20 shows the expression of marker protein on rod cells after introduction of RNA virus.
- FIG. 21 is a graph showing the ability of DCs transfected with RNA viruses to stimulate T cells.
- FIG. 22 shows the induction of proliferation of antigen-specific T cells in rod cells into which RNA virus has been introduced.
- FIG. 23 shows the results of in vitro induction of MART-1-specific CTL by introduction of RNA virus.
- FIG. 24 shows a growth curve of B16 melanoma cells inoculated subcutaneously.
- FIG. 25 shows the results of 51 Cr release assembly for YAC-1 target cells.
- FIG. 26 shows the results of 51 Cr release assembly of TRP2 peptide + EL-4.
- FIG. 27 shows the therapeutic effect on melanoma by in vivo administration of GFP-expressing SeV, soluble FGF receptor-expressing SeV, or soluble PDGFR ⁇ -expressing SeV.
- FIG. 28 is a graph showing the therapeutic effect on melanoma by ex vivo administration of rod cells transfected with GFP-expressing SeV or soluble PDGFRa-expressing SeV.
- RNA virus refers to a virus having an RNA genome.
- the RNA virus is preferably a virus that synthesizes RNA in the form of RNA in the life cycle of the virus.
- the RNA virus may be a wild-type virus that replicates genomic RNA in a rod-shaped cell, or may be a mutant virus such as an attenuated virus or a temperature-sensitive virus. It can be a natural virus (a naturally occurring virus) or a recombinant virus.
- RNA viruses include single stranded RNA viruses (including positive and negative stranded RNA viruses) and double stranded RNA viruses.
- viruses including enveloped viruses (envelope viruses) and viruses without envelopes (non-envelope viruses) are used, but envelope viruses are preferably used.
- RNA viruses specifically include viruses belonging to the following families. Arenaviridae such as Lassa virus
- Orthomyxoviridae such as influenza virus
- Coronaviridae such as SARS virus
- Togaviridae such as rubella virus
- Paramyxovindae mumps virus, measles virus, Sendai virus, RS virus
- Picornaviridae such as poliovirus, cricket virus, echovirus
- Flaviviridae such as Marburgda virus, Ebola virus, etc. (Floviridae) Flaviviridae, such as yellow fever virus, dengue virus, hepatitis C virus, hepatitis G virus
- Rhabdoviridae such as rabies virus
- a rod-like cell into which an RNA virus having genome replication ability is introduced is a rod-like cell containing genomic RNA of an RNA virus having genome replication ability, wherein the RNA is A cell in which the RNA replicates in a rod-shaped cell due to the viral protein to be coded.
- RNA virus genomic RNA and viral protein that binds to the RNA form a ribonucleoprotein (RNP) complex in the cell and replicate the genomic RNA in the cell.
- RNP ribonucleoprotein
- a rod-like cell into which an RNA virus having genome replication ability is introduced means a rod-like cell having a ribonucleoprotein (nucleocabside) of an RNA virus having genome replication ability.
- the RNA virus may be infected by contacting the rod-shaped cell or its precursor cell with infectious RNA virus particles.
- infectious virus particles RNPs contained in RNA viruses with genome replication ability can be introduced into cells, or virus particles that are not infectious and contain the RNPs (Non-infectious virus particles, or virus-like particles (VLP)) may be introduced into cells.
- RNP virus
- virus-like particles VLP
- viral genomic RNA can be replicated in the cell if it is introduced into a rod-shaped cell (W097 / 16538; WO00 / 70055).
- an expression vector encoding a viral genomic RNA and a viral protein necessary for replication of the genomic RNA (N, P and L proteins in the case of a minus-strand RNA virus) is introduced into a rod-shaped cell, and the rod-shaped cell is then introduced.
- RNP form inside In order to introduce RNP or VLP into rod cells or their progenitor cells, a well-known transfection method can be used. Specifically, calcium phosphate (Chen, C. & Okayama, H. (1988) BioTechniques 6: 632-638; Chen, C. and Okayama, H., 1987, Mol. Cell. Biol. 7: 2745 ), DEAE-dextran (Rosenthal, N. (1987) Methods Enzymol. 152: 704-709), various ribosome-based transfection reagents (Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY)), Electro Pole
- transfusion reagents are DOTMA (Roche), Superfect Transfection Ragent (QIAGEN, Cat No. 301305), DOTAP, DOPE, DOSPER (Roche # 1811169), TransIT—LTl (Mirus, Product No. MIR 2300 ), CalPhos TM Mammalian Transfection Kit (Clontech # K2051-1),
- CLONfectin TM (Clontech # 8020-1).
- enveloped viruses are known to take up host cell-derived proteins during virus particle formation, and such proteins can cause antigenicity and cytotoxicity when introduced into rod cells. (J. Biol. Chem. (1997) 272, 16578-16584). Therefore, there is an advantage in introducing RNP from which the envelope has been removed into rod cells (WO00 / 70055).
- RNA virus When an RNA virus is introduced, replication of the viral genome occurs in the rod cells, and activation of the rod cells is induced to differentiate into mature rod cells. The resulting mature rod cells retain the ability to activate T cells.
- a rod-like cell into which an RNA virus has been introduced has a high ability to activate the immune system, and can exert an anticancer effect when administered to a tumor.
- Infection of rod-shaped cells with RNA virus can be performed in vitro (or ex vivo) in a desired physiological aqueous solution such as a culture solution or physiological saline.
- the present invention is useful for ex vivo anti-tumor treatment in which rod-like cells or progenitor cells taken out from the body are contacted with an RNA virus outside the body, and the virus is introduced into the body after introduction.
- RNA viruses When infecting RNA viruses in vitro, it is preferable to contact RNA viruses with immature rod cells or to mix with cell fractions containing immature rod cells.
- RNA virus Alternatively, cells can be activated by contact with bacteria or lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- the RNA virus may be introduced after activation, but in order to prevent the efficiency of virus introduction from being reduced, the activation procedure is not performed. It is preferable to perform this after introducing the virus (or at the same time as bringing the virus into contact with the rod-shaped cells) rather than before introducing the virus.
- the MOI multiplicity of infection; the number of infected viruses per cell
- the MOI is preferably between 1 and 500, more preferably 2 ⁇ 300, more preferably 3 to 200, more preferably 5 to 100, more preferably? ⁇ 70.
- the contact between the RNA virus and the rod-shaped cells is sufficient even for a short time, for example, 1 minute or more, preferably 3 minutes or more, 5 minutes or more, 10 minutes or more, or 20 minutes or more. It may be about ⁇ 60 minutes, more specifically about 5 to 30 minutes. Of course, the contact time may be longer than that, for example, it may be contacted for several days or longer.
- Dendritic cells are cells that are matured, take a dendritic form, and have the ability to activate T cells by presenting antigens.
- the rod-shaped cells are divided into a bone marrow-derived cell group distributed in various tissue organs in the living body and stem cells derived from bone marrow or blood using in vitro site force-in. This includes a group of cells equivalent to cells having a dendritic morphology distributed in tissue organs in vivo.
- the rod cells include, for example, lymphoid rod cells (which may induce Th2 induction or immune tolerance), myeloid rod cells (generally used rod cells).
- follicular rod cell important as an antigen-presenting cell to B cell, antigen-antibody complex, antigen-complement complex is presented on rod-shaped cell by antibody receptor and complement receptor And so on
- MHC class I and class II are highly expressed, and more preferably CD1 lc is expressed! / It is a cell.
- the rod-shaped cell has a toothpick morphology and is selected from the group consisting of CDllc, HLA-class II (HLA-DR, -DP, or -DQ), CD40, and CDla. Two or more of the surface markers may be positive cells. In the present invention, the rod cells are more preferably
- HLA-class 11+ and CDllc + cells more preferably CDla +, HLA-class II + and CDllc + cells, and T cell markers (CD3), B cell markers (CD19, CD20), NK cell markers (CD56), A cell does not express a neutrophil marker (CD15) or a monocyte marker (CD14).
- the proportion of CD14 + in the rod cell population used for the introduction of RNA virus is, for example, 10% or less, preferably 5% or less, more preferably 1% or less.
- the rod cells include mature rod cells and immature rod cells.
- Immature rod cells refer to rod cells that have a low ability to activate T cells.
- immature rod cells have an antigen-presenting ability of less than half, preferably LPS (1 micro-g / ml) added and cultured for 2 days to induce maturation, preferably It may be less than 1/4.
- Antigen-presenting ability is, for example, the ability to activate T cells (mixed lymphocyte test; mixed culture of T cells and rod cells, and the ratio of T cells to rod cells is 1:10, preferably Fig. 21 shows the amount of T cells proliferated by adding 3 H-thymidine and quantifying the amount of T cells taken up into the DNA 8 hours before the end of the culture.
- cytotoxic T cell CTL inducing ability test using peptides Co-cultured T cells from the same healthy human peripheral blood from which the rod-shaped cells were collected by adding known peptides (IL-2 at 25 U / ml, preferably 100 U / ml after the third day) (preferably (Stimulation of rod cells three times for 21 days, more preferably stimulation of rod cells twice for 14 days), and the obtained effector cell with 51 Cr.
- known peptides IL-2 at 25 U / ml, preferably 100 U / ml after the third day
- stimulation of rod cells three times for 21 days, more preferably stimulation of rod cells twice for 14 days
- immature mature rod cells preferably have antigen phagocytic ability, and more preferably have low expression of receptors that induce costimulation for T cell activity (for example, mature DCs induced by LPS as described above). Significantly) or negative.
- mature rod cells are rod cells that have a high antigen-presenting ability for T cell activation.
- mature rod cells are added to LPS (1 micro-g / ml) and cultured for 2 days to induce maturation of 1/2 or more, preferably equal to or greater than the antigen presenting ability of rod cells. It may be a cell having an antigen presenting ability.
- mature rod cells are preferably cells that have low or no antigen phagocytosis, and more preferably have high expression of receptors that induce costimulation for T cell activation.
- the activation of rod cells means the transition from immature rod cells to mature rod cells, and activated rod cells are co-stimulated with mature rod cells and activation stimuli. Included in that category are intermediate cells that are elevating the expression of CD80, CD86 to induce. For CDllc-positive cells, CD83-positive is an indicator of mature cells.
- the mature rod-shaped cell may be a cell that is preferably strongly positive for the expression of CD40, CD80, CD86 and HLA-class II. More preferably, the mature rod cells express CD83.
- immature rod cells and mature rod cells can be distinguished based on a marker selected from the group consisting of CD80, CD83, and CD86. These markers are weak or preferably negative in immature rod cells and positive in mature rod cells.
- immature rod cells usually have high phagocytic activity! /.
- LPS (1 micro-g / ml)
- the rod cells are activated and their phagocytic ability decreases.
- the phagocytic ability can be determined by measuring the amount of small molecules taken into the rod cells or the proportion of cells taken up.
- the phagocytic ability is determined by the amount of small molecule taken up into rod cells.
- the uptake of beads into rod cells can be measured using colored beads of about 1 micro-m. Subtract the positive background at 4 ° C and quantify.
- the high phagocytic ability means that the amount of small molecules taken up into the rod cells is 4 times or more that of rod cells stimulated with LPS (1 micro-g / ml) for 2 days as described above, The phagocytic ability is more preferably 5 times or more, more preferably 6 times or more. Alternatively, small molecule uptake The percentage power of the cells is 3 times or more, more preferably 3 times or more.
- Low phagocytic capacity means that small molecule uptake into rod cells is less than 4 times, more preferably less than 2 times, more preferably that of rod cells stimulated with LPS (1 micro-g / ml) for 2 days. Is less than 1.5 times. Alternatively, it is less than 2-fold, more preferably less than 1.5-fold, as measured by the percentage of small molecule uptake cells.
- CDl lc is an approximately 150 kD adhesion glycoprotein (pl50, integrin alpha chain). It has been reported that CDllc binds to CD18 to form a CDllc / CD18 complex, has a binding ability to fibrinogen, and is a receptor for iC3b and ICAM-1. In addition, CDllc / CD18 has been reported to be able to act as an adhesion molecule that binds to stimulated epithelial receptors (Knapp, W.
- CDla is an approximately 49 kD polypeptide that binds beta 2 microglobulin. CDla is structurally similar to the MHC class I antigen and is considered to function in antigen presentation (Knapp, W. et al., Eas., 1989, Leucocyte Typing IV: White and ell Differentiation Antigens, Oxford University Press, New York; Scnlossman, S. et al., Eds., 199b, Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York; Hanau, D. et al., 1990, J. Investigative Dermatol. 95: 503 Calabi, F. and A. Bradbury., 1991., Tissue Antigens 37: 1).
- CD14 is a 53-55 kD glycosylphosphatidylinositol (GPI) -anchored single-chain glycoprotein that is expressed in reticulocytes and certain Langerhans cells.
- CD14 has been identified as a high-affinity surface receptor for LPS and serum LPS-binding protein (LPB) complex (McMichael, AJ et al., Eds., 1987, Leucocyte Typing III: White Cell Differentiation Antigens, Oxford University Press, New York; Knapp, W. et al., Eds., 1989, Leucocyte Typing IV: White Cell Differentiation Antigens, Oxford University Press, New York; Schlossman, S. et al "eds., 1995, Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York; Wright, SD et al "1990, Science 249: 1434)
- CD40 is a 45-48 kD type I integral membrane glycoprotein, and anti-CD40 antibody is often used as a cell marker (Schlossman, S. et al., Eds., 1995, Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York; Galy, AHM; and H. Spits, 1992, J. Immunol. 149: 775; Clark, EA and JA Ledbetter, 1986, Proc. Natl. Acad. Sci. 83: 4494; Itoh, H. et al "1991, Cell 66: 233; Barclay, NA et al" 1993, The Leucocyte Antigen Facts Book., Academic Press).
- CD80 is a transmembrane glycoprotein of about 60 kD and is a member of the Ig supergene family.
- CD80 is a ligand for CD28 and CD152 (CTLA-4) expressed in T cells (Schlossman, S. et al., Eas., 1995, Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York; Schwarts , RH, 1992, Cell 71: 1065; Azuma, M. et al., 1993, J. Exp. Med. 177: 845; Koulova, L. et al., 1991, J. Exp. Med. 173: 759; Freeman, GJ et al "1998, J.
- CD83 is a transmembrane protein of about 45 kD and a member of the Ig superfamily. CD83 has a short V-type Ig extracellular domain and a C-terminal cytoplasmic tail. CD83 is expressed primarily on follicular cells, circulating cells, interdigitating cells of lymphoid tissues, cells generated in vitro, and thymic cells (Zhou, LJ. , and TF Tedder, 1995, J. Immunol. 154. 3821; Zhou, LJ. et al., 1992, J. Immunol. 149: 735; Summers, KL et al "1995, Clin Exp. Immunol. 100: 81; Weissman, D. et al "1995, Proc. Natl. Acad. Sci USA. 92: 826; Hart, DNJ, 1997, Blood 90: 3245).
- CD86 (B70 / B7-2) is a cell surface protein of approximately 75 kD, the second ligand for CD28 and CTLA-4, and plays an important role in T cell costimulation in the initial immune response (Azuma M. et al "1993, Nature 366: 76; Nozawa Y. et al., 1993, J. Pathology 169: 309; Engle, P. et al. 1994., Blood 84: 1402; Engel, P. et al" CD86 Workshop Report. In: Leukocyte Typing V. Schlossman, SF et al.
- CCR7 is a seven-transmembrane G protein-binding receptor, also called BLR-2, EBI-1, and CMKBR7, and is a CC chemokine, MIP-3beta / Exodus 3 / ELC / CCL19 and
- HLA-class II includes DR, DP, and DQ, and can be comprehensively detected by antibodies that bind to all of them (Pawelec, G. et al., 1985, Human Immunology 12: 165; Ziegler , A. et al., 1986, Immunobiol. 171: 77).
- HLA-DR is one of the human class II antigens of MHC and is a transmembrane glycoprotein with alpha chain (36 kDa) and beta subunit (27 kDa) forces. It is co-expressed with CDla antigen in epidermal Langernon cells. CDla plays a major role in cell interaction over antigen presentation (Barclay, N.A. et al., 1993, The Leucocyte Antigen Facts Book. P. 376. Academic Press).
- rod cells can be identified using the homologous gene product of the marker gene as an index.
- Antibodies against these markers can be obtained from, for example, BD Biosciences (BD PharMingen), details of which can be found on the website of the company or distributor.
- the positive rate is determined to be positive with a fluorescence intensity of 1% or less as a boundary, and less than that is determined to be negative.
- rod-like cells or progenitor cells thereof can be performed according to or according to a known method.
- forces such as blood (eg, peripheral blood or umbilical cord blood), bone marrow, lymph nodes, other lymphoid organs, spleen, skin, etc.
- rod cells are obtained from blood or bone marrow strength for use in the present invention.
- the rod-shaped cells used in the present invention include skin Langer-Nonce cells, imported lymphatic veil cells, follicular rod cells, spleen rod cells, and lymphoid finger cells. Also good.
- the rod cells used in the present invention include CD34 + -derived rod cells, bone marrow-derived rod cells, monocyte-derived rod cells, splenocyte-derived rod cells, skin-derived rod cells, follicular rod cells, And a rod cell selected from the group consisting of germinal center rod cells.
- CD34 + -derived rod cells are derived from hematopoietic stem cells or hematopoietic progenitor cells obtained from umbilical cord blood or bone marrow, and granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis It can be separated by cis factor (TNF) -alpha, IL-4, IL-13, stem self-actor (SCF), Flt-3 ligand, c-kit ligand, or a combination thereof.
- G-CSF granulocyte colony-stimulating factor
- GM-CSF granulocyte-macrophage colony-stimulating factor
- TNF cis factor
- peripheral blood monocytes can be differentiated into immature rod cells by GM-CSF and IL-4, and further differentiated into mature rod cells by stimulation with TNF-alpha.
- rod cells it is possible to concentrate rod cells by removing these cells using antibodies specific to T cells, NK cells, B cells and the like.
- a cell whose expression of a surface marker selected from CD2, CD3, CD8, CD19, CD56, CD66b or any combination thereof is low or negative. More preferably, CD2, CD3, CD8, CD19, CD56, and CD66b are all low or negative cells.
- cells expressing these markers may be removed using antibodies against these markers (Hsu et al. (1996) Nature Med. 2:52).
- the negative selection can be carried out using such a multivalent antibody as shown in this Example, or beads or the like can be used for magnetic cell separation (MACS).
- beads For example, rod-shaped cells prepared by enriching cell solution-strengthened monocytes obtained from a living body and performing negative selection on the cells can be suitably used in the present invention.
- the efficiency of virus introduction may be reduced.
- the rod-shaped cells used in the present invention are not limited to this, but the cell culture prior to contact with the RNA virus should be a solid support (for example, a culture) so as not to reduce the ratio of immature rod-shaped cells. It is preferable not to include a step of selecting cells adhered to a culture container such as a dish or a bottle. That is, the present invention provides a method that does not include the step of selecting cells attached to a solid support within 24 hours prior to the contact between the RNA virus and the rod-shaped cells. More preferably, the step of selecting cells attached to the solid support should not be included within 2, 3, 5, or 7 days prior to contact of the RNA virus with the rod cells. Yes.
- the step of selecting is not included. That is, the present invention provides a method that does not include the step of selecting CD14 + cells within 24 hours prior to the contact between the RNA virus and the rod cells. More preferably, the step of selecting CD14 + cells should not be included within 2, 3, 5, or 7 days prior to contact of the RNA virus with the rod cells.
- rod-shaped cells from CD34 + cells and peripheral blood-derived mononuclear cells from which bone marrow, umbilical cord blood, or peripheral blood isotherm can be obtained, see Van Tendeloo et al., 1998, Gene Ther. 5: 700-707. It may be carried out using the method described.
- rod-shaped cells or their progenitor cells for example, CD1 lc + cells or
- RNA virus into a cell fraction containing CD34 + cells
- Progenitor cells are suitable site-in (ie G-CSF, GM-CSF, TNF-alpha, IL-4, IL-13, SCF, Flt-3 ligand, c-kit ligand, or combinations thereof) Cells that can be separated into rod cells in the presence of, preferably within 4 weeks, more preferably within 20 days, more preferably within 18 days, more preferably within 16 days. It is a cell that can be separated.
- Such cells include CD34 + stem cells.
- the cell fraction is a cell population obtained by cell separation (or fractionation).
- the cell fraction may be a composition comprising cells and a pharmaceutically acceptable carrier.
- the carrier include a desired solution capable of suspending living cells, such as physiological saline, phosphate buffered saline (PBS), culture solution, and serum.
- the proportion of rod-like cells and Z or precursors thereof in the whole living cells is, for example, 30% or more, preferably 40% or more. It is preferably 50% or more, preferably 60% or more, preferably 70% or more.
- immature rod cells are contained in the rod cells to be contacted with the RNA virus.
- the ratio of immature rod cells in all living cells is, for example, 10% or more, preferably 20% or more, more preferably 30% or more, more preferably It is 40% or more, more preferably 50% or more, more preferably 60% or more, more preferably 70% or more.
- RNA virus if an RNA virus is used, active rod cells can be obtained only by virus infection, and the subsequent step for obtaining mature rod cells can be omitted. In order to use rod-shaped cells for immunostimulation, activity is required, so there is an advantage in that activity can be caused only by virus infection.
- activated T cells necessary for T cell transfer therapy in vitro particularly cytotoxic T cells can be efficiently induced in a short period of time. CTLs cannot be induced in cells that have been introduced by viruses, and CTL induction in vitro is not possible by gene transfer of other viral vectors alone due to the properties previously reported for other viral vectors. Have difficulty. Therefore, RNA viruses have the advantage that T cells can be activated (CTL induction) only by introducing the virus (see FIGS. 21 to 23).
- the rod-shaped cells may be separated after gene transfer of the RNA virus into the stem cells.
- the Sendai virus is introduced into stem cells and then induced to differentiate into rod cells, the gene transfer efficiency reaches nearly 70%. This is comparable to modified versions of retrovirus and lentiviral vectors.
- Adenovirus vectors are difficult to introduce genes from stem cells because their expression decreases due to dilution of episomes after introduction.
- Preparation of rod-shaped cells into which genome-replicating RNA virus has been introduced includes the method of differentiation of rod-shaped cells after introduction into stem cells, the method of introducing genes into rod-shaped cells differentiated from peripheral blood mononuclear cells, Either of these methods is possible.
- RNA virus If the MOI is increased (for example, 10 or more, preferably 20 or more, more preferably 30 or more, for example 40 or more, or even 50 or more) when RNA virus is infected, it has a significant effect on cytotoxicity. It can be expected to be stably introduced into cells with an introduction efficiency of almost 100%. Furthermore, using an RNA virus that does not integrate the genome into the host chromosome has the advantage that the risk of tumor development due to host genome alteration is low. In this respect, RNA viruses other than retrovirus are preferably used.
- RNA virus not only a recombinant virus but also a natural virus can be used.
- virology You can refer to Experimental Studies, 2nd edition (National Institute of Preventive Health, Alumni Association, Maruzen, 1982).
- Paramyxoviridae's Sendai virus and other parainfluenza viruses grow well in monkey kidney (MK2), human fetal lung, kidney, amnion primary culture cells, and trypsin supplemented Vero cells. (P334; Itoh H et al., Jap. J. Med. Sci. Biol. 23, 227 (1970)).
- Purification can be achieved by sucrose density gradient centrifugation, equilibrium centrifugation, etc. (p336). Measles virus can proliferate well in various monkey-derived cells (Matsumoto M, Bact. Rev. 30, 152 (1966)). Vero cells use the most widely used force CV1, FL, KB, HeLa HEp2, etc. (P351). In Rhabdoviridae, such as rabies virus, BHK, CE, and Vero cells are used using tissue culture methods. As a purification method, the culture solution on the 3rd to 4th day of infection is corrected to pH 7.4 or higher, and the cell debris is removed by high-speed centrifugation (p376).
- Arenaviridae such as Lassa virus
- GMK primary African green monkey kidney cells
- Vero Vero
- BHK21, RK13 primary quail or ⁇ embryo cells
- R66 and SIRC cells.
- Orthomyxoviridae virus family such as 0 influenza virus (Orthomyxoviridae) can grow in embryonated chicken eggs or MDCK cells (P295). Purification can be achieved by centrifugal fractionation, purification by adsorption to red blood cells (Laver WG, Fundamental Techniques in Virology, 82 (I 969 )) 7 ).
- the RNA virus may be a virus that has been isolated from natural forces or may be a virus that has been artificially created by genetic recombination. Moreover, as long as it retains the ability to replicate genomic RNA in infected cells, any viral gene possessed by the wild-type virus may be mutated and / or deleted. For example, a virus having a mutation or deletion in at least one gene encoding a viral envelope protein or coat protein can be preferably used. Such viruses can replicate the RNA genome in infected cells, but cannot form infectious virus particles. Therefore, there is no concern of spreading the infection to the surrounding area, so safety is high.
- RNA virus in a minus-strand RNA virus, use a virus that contains at least one gene that codes for an envelope protein such as F, H, HN, or G or a spike protein, or a combination thereof.
- an envelope protein such as F, H, HN, or G or a spike protein, or a combination thereof.
- Genomic RNA can be amplified in infected cells if the RNA required for genome replication (eg, N, P, and L proteins) is encoded by genomic RNA.
- a genomic RNA encoding at least N, L, and P proteins and an RNP containing these proteins, and a viral particle containing the RNP are introduced into the rod cells in the production of the antitumor agent of the present invention.
- a defective virus for example, a defective gene product or a protein capable of complementing it is supplied exogenously in virus-producing cells (WO00 / 70055 and WO00 / 70070; Li, H.-O. et al., J. Virol. 74 (14) 6564-6569 (2000)).
- non-infectious virus particles can be used without a gene encoding a spike protein such as F protein or HN protein if the virus has an M protein gene.
- VLP non-infectious virus particles
- RNP consisting of N, L, P protein, and genomic RNA
- the obtained VLP or RNP can be mixed with a desired transfection reagent and introduced into the cells on the cell to produce an antitumor agent.
- the antitumor agent of the present invention can also be produced using a mutant RNA virus.
- temperature-sensitive mutations are known in envelope proteins and outer shell proteins.
- RNA viruses having these temperature-sensitive mutant protein genes can be preferably used in the present invention.
- a temperature-sensitive mutation is a mutation that is significantly less active at normal temperatures (eg, 37 ° C to 38 ° C) of the virus host than at low temperatures (eg, 30 ° C to 32 ° C).
- Such a protein having a temperature-sensitive mutation is useful because a virus can be produced at an allowable temperature (low temperature).
- the temperature-sensitive mutation of the M gene of the minus-strand RNA virus includes amino acid substitution at a site arbitrarily selected from the group consisting of G69, T116, and A183 in the Sendai virus M protein (Inoue, M. et al., J. Virol. 2003, 77: 3238-3246). Amino acids at other minus-strand RNA virus M protein homologous sites can be easily identified.
- homologous sites of each M protein corresponding to T116 of SeV M protein are human parainfluenza virus-1 (HPIV-1) and 3 ⁇ 4> is ⁇ 116, human parainfluenza.
- T120 for virus-3 (HPIV-3) T104 for phocine distemper virus (PDV) and canine distemper virus (CDV)
- T105 for dolphin molbillivirus (DMV) peste—des—petits— ruminants virus ( PDPR), measles virus (MV) and O, rinderpest virus
- the homologous site of each M protein corresponding to A183 of SeV M protein is A183 for human parainfluenza virus-1 (HPIV-1), F187, phocine distemper virus, whether it is human parainfluenza virus-3 (HPIV-3) YPD for PDV and canine distemper virus (CDV), Y172 for dolphin molbillivirus (DMV), peste-des-petits-ruminants virus (PDPR), measles virus (MV) and rinderpest virus (RPV) That is Y171, Hendra virus (Hendra) and Nipah virus (Nipah) Y187, human parainfluenza virus-2 (HPIV-2) Y184, F184 for simian parainfluenza virus 5 (SV5), F188 for human parainfluenza virus-4a (HPIV-4a) and human parainfluenza virus-4b (HPIV-4b), F186 for mumps virus (Mumps) Newcastle disease virus (NDV) is Y187.
- each M protein has the power of any of the above 3 sites, preferably a combination of any 2 sites, and more preferably all 3 sites are replaced with other amino acids.
- a virus having a genome encoding a protein is preferably used in the present invention.
- Amino acid mutations are favored by substitution with other amino acids with different side chain chemistries such as the BLOSUM62 matrix (Henikoff, S. and Henikoff, J. G. (1992) Proc. Natl. Acad. Sci. USA 89:
- the homologous sites of Sendai virus M protein G69, T116, and A183 or other viral sputum proteins can be replaced with Glu (E), Ala (A), and Ser (S), respectively.
- M protein of P253-505 (Morikawa, Y. et al, Kitasato Arch. Exp. Med. 1991: 64; 15-30) It is also possible to use mutations that are homologous to quality mutations. Mutation can be introduced according to a known mutagenesis method using, for example, an oligonucleotide.
- the temperature-sensitive mutation of the HN gene includes, for example, amino acid substitution at a site arbitrarily selected from the group consisting of A262, G264, and K461 of the Sendai virus HN protein (Inoue, M. et al. ., J. Virol. 2003, 77: 3238-3246).
- the homologous sites of Sendai virus HN protein A262, G264, and K461 or other viral HN proteins are substituted with Thr (T), Arg (R), and Gly (G), respectively.
- mutations can be made to amino acids 464 and 468 of the HN protein (Wright, KE et al., Virus Res. 2000: 67; 49- 57).
- the minus-strand RNA virus may have a mutation in the P gene or L gene.
- mutations include SeV P protein 86th Glu (E86) mutation, SeV P protein 511st Leu (L511) substitution to other amino acids, or other negative strands.
- RNA virus P protein homologous site replacement Specific examples include substitution of the 86th amino acid with Lys and substitution of the 511st amino acid with Phe.
- Mutations in the P and L genes can significantly enhance the effects of persistent infectivity, suppression of secondary particle release, or suppression of cytotoxicity. Furthermore, by combining mutations and / or deletions in the envelope protein gene, these effects can be dramatically increased.
- a rod-shaped cell may be infected with a virus containing a protein different from the envelope protein inherent in the virus.
- a virus when a virus is produced, a desired foreign envelope protein is expressed in a virus-producing cell, whereby a virus containing the protein can be produced.
- a desired protein that imparts the ability to infect mammalian cells is not particularly limited. Specifically, for example, vesicular stomatitis virus (VSV) Of G protein (VSV-G).
- VSV-G protein can be derived from any VSV strain.
- the VSV-G protein derived from the Indiana serotype strain J. Virology 39: 519-528 (1981)
- the RNA virus used in the present invention can contain any combination of envelope proteins derived from other viruses.
- RNA viruses may encode foreign genes in genomic RNA! /, Or not! /.
- the present invention has an advantage that a desired RNA virus such as a wild-type RNA virus or a virus isolated from a natural force (including mutants) can be used.
- a desired RNA virus such as a wild-type RNA virus or a virus isolated from a natural force (including mutants)
- RNA virus to be used an RNA virus that does not encode a protein having a cancer therapeutic effect can be used.
- viruses include RNA viruses that encode desired foreign proteins that do not have cancer therapeutic effects.
- green fluorescent protein (GFP), luciferase various peptides
- an RNA virus encoding a marker protein such as a tag can be used.
- the anticancer effect can be further enhanced by further incorporating a foreign gene that assists the anticancer effect in the RNA virus.
- Recombination of a recombinant RNA virus having a foreign gene may be performed using a known method.
- the specific procedure typically involves (a) transcribing the cDNA encoding the RNA viral genomic RNA in a cell that expresses the viral proteins required for virus particle formation, and (b) including the resulting virus. It can be produced by a step of collecting the culture supernatant.
- Viral proteins may be expressed from transcribed viral genomic RNA or supplied to trans from other than genomic RNA. When the viral RNA necessary for particle formation is deficient in genomic RNA, the virus gene is separately expressed in virus-producing cells to complement particle formation.
- a vector in which DNA encoding the protein or genomic RNA is linked downstream of an appropriate promoter that functions in the host cell is introduced into the host cell.
- Transcribed genomic RNA is replicated in the presence of viral proteins to form infectious viral particles.
- defective viruses that lack genes such as envelope proteins, Or other viral proteins that can complement their functions are expressed in virus-producing cells.
- RNA virus in the production of a minus-strand RNA virus, the following known methods can be used (W097 / 16539; W097 / 16538; WO00 / 70055; WO00 / 70070;
- minus-strand RNA viruses including palinfluenza, vesicular stomatitis virus, rabies virus, measles virus, Linda-pest virus, Sendai virus, etc.
- a minus-strand RNA virus particularly a single-strand minus-strand RNA virus, more preferably a paramyxoviridae virus, more preferably a respirovirus genus virus can be suitably used.
- a method for producing a rod-shaped cell into which a minus-strand RNA virus having genome replication ability has been introduced is a cell that expresses viral proteins (N, P, and L) necessary for genome replication. Introduce or transcribe viral genomic RNA (minus strand) or its complementary strand (plus strand). N, P, and L proteins are supplied, for example, by introducing an expression plasmid that expresses these proteins into cells. Viral genomic RNA that encodes viral proteins (N, P, and L) required for genome replication is used. If this process is performed in rod cells, genomic RNA and RNP containing N, P, and L are formed in the rod cells, and the RNP can be replicated autonomously in the rod cells.
- the generated RNP Collect infectious or non-infectious virus particles.
- M protein is present, the virus force (or VLP) is also released by the action of cellular force.
- VLP virus force
- these spike proteins are incorporated into the formed particles and become infectious virus particles.
- non-infectious virus particles are released in the presence of M protein.
- the recovered RNP or VLP is introduced into the cells together with, for example, a transfection reagent. Infectious virus particles can be added to rod cells as they are for infection. Thus, rod-shaped cells into which a minus-strand RNA virus has been introduced can be produced.
- Examples of the method for producing a plus (+) strand RNA virus include the following examples.
- Novel design architecture for genetic stability of recombinant poliovirus the manipulation of G / C contents and their distribution patterns increases the genetic stability or inserts in a poliovirus— based RPS-Vax vector system. J Virol. 2002 Feb; 76 (4): 1649-62.
- Reovirus reverse genetics Incorporation of the CAT gene into the reovirus genome.
- proteins include, for example, hormones, cytosites, growth factors, receptors, intracellular signal molecules, enzymes, antibodies (full-length antibodies, Fabs, etc. Antibody fragments, single chain antibodies, etc.), peptides, etc.
- the protein can be a secreted protein, a membrane protein, a cytoplasmic protein, a nucleoprotein, and the like.
- Artificial proteins include, for example, fusion proteins such as chimeric toxins, dominant negative proteins (receptor soluble molecules or membrane-bound dominant negative receptors). And deletion type cell adhesion molecules and cell surface molecules.
- RNA molecules or RNA-cleaving ribozymes can be expressed as transgenes to suppress the function of specific genes. If a virus is prepared using a therapeutic gene exhibiting anticancer activity as a foreign gene, the anticancer activity can be further enhanced.
- fibroblast growth factor 2 (FGF2) (Balfour, R. et al., J. Vase. Surg. 16 (2): 181-91, 1992), endothelium.
- Endothelial cell growth factor (ECGF) (Pu, LQ et al., J. Surg. Res. 54 (6): 575-83, 1993), vascular endothelial growth factor / vascular permeability growth factor; VEGF I vascular permeability factor; VPF) (Takeshita, S.
- RNA viruses encoding soluble polypeptides of the FGF receptor are preferably used in the present invention, and can be used as a soluble FGF-R.
- Natural soluble FGF-R can be used, or a fragment consisting of the extracellular domain of membrane-bound FGF-R (such as FGF-R1) can be used (A. Hanneken and A. Baird,
- a cancer antigen peptide expressed by a target cancer can also be presented to a rod-shaped cell.
- the antigen to be presented to the rod cells can be encoded by an RNA virus, added to the rod cells into which the RNA virus has been introduced (ie, pulsed), or expressed in another desired vector.
- the tumor antigen is preferably specific to the tumor cell (ie, present in the tumor cell but not present in the non-tumor cell), but present at a higher level in the tumor cell than in the same type of non-tumor cell You may do. Further, it may be the full length of the cancer antigen protein or a partial peptide thereof. By identifying a peptide presented in rod cells, the peptide can be synthesized and used. Antigen peptides bind to MHC molecules on the surface of rod cells and are presented on the cell surface, inducing an immune response.
- a desired tumor antigen expressed inside or outside the cell can be used as an antigen.
- the antigen is expressed on the cell surface.
- cell surface receptors or cell adhesion proteins can be used.
- tumor antigens include Muc-1 or Muc-1-like mucin tandem repeat peptides (US Pat. No.
- a rod-like cell into which a gene encoding site force-in is introduced is also useful. It is. A rod cell in which an RNA virus carrying a gene encoding an immunostimulatory site force-in is introduced becomes an effective tumor immunity inducer.
- interleukins eg IL-lalpha, IL-lbeta, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-9 , IL-10, IL-12, IL-15, IL-18, IL-19, IL-20, IL-21, IL-23, IL-27
- interferon eg, IFN-alpha, IFN-beta, IFN-gamma
- TGF tumor necrosis factor
- TGF transforming growth factor
- TGF transforming growth factor
- M-CSF Macrophage colony stimulating factor
- GM-CSF insulin-like growth factor
- IGF insulin-like growth factor
- IL-4 for example, Arai et al. (1989), J. Immunol. 142 (1) 274-282, IL-6
- IL-12 for example, Wolfe (1991), J. Immunol. 146 (9): 3074-3081, IFN-alpha
- IFN-beta is, for example, Accession number NM_002176 139 ⁇ 636th sequence (amino acid sequence is 22 to 187 of NP_002167) (Derynck, R. et al., Nature 285, 542-547 (1980); Higashi, Y. et al, J. Biol. Chem. 258, 9522-9529 (1983); Kuga, T. et al., Nucleic Acids Res. 17, 3291 (1989)).
- TNF is, for example, Pennica et al. (1984) Nature 312: 724-729
- G-CSF is, for example, Hirano et al.
- GM-CSF is, for example, Cantrell et al. (1985). Proc. Natl. Acad. Sci. (USA) 82 (18): 6250-6254. More specifically, the nucleic acid sequence encoding GM-CSF includes a sequence containing the 84th to 461st sequences of Accession number NM_000758 (the amino acid sequence is 18th to 144th of NP_000749). Examples of the nucleic acid sequence encoding IL-4 include a sequence containing the 443-829th sequence of Accession number NM_000589 (the amino acid sequence is 25-153 of NP_000580).
- the signal peptide sequence may be appropriately replaced with the signal peptide sequence of another protein.
- mutant genes encoding functional site force ins can be constructed and introduced into rod cells.
- the gene may be genetically modified so as to express a modified version of these cyto force-ins.
- a site force-in that has two forms, a precursor and a mature form (for example, one that generates an active fragment by cleavage of a signal peptide or one that generates an active fragment by limited degradation of a protein)
- Genetic modifications may be made to express either precursors or matures.
- Other variants e.g., the cytoplasmic activity activity flag Or a heterologous sequence (eg, a heterologous signal peptide).
- the rod cells into which the RNA virus has been introduced can be combined with a desired pharmacologically acceptable carrier or medium (eg, physiological saline, Ringer's solution, culture solution, serum, etc.) as necessary. . If necessary, concentrate it by centrifugation and resuspend it in a physiological solution such as a culture solution or physiological saline!
- a desired pharmacologically acceptable carrier or medium eg, physiological saline, Ringer's solution, culture solution, serum, etc.
- a physiological solution such as a culture solution or physiological saline
- the rod cells prepared according to the present invention are useful in effective immunotherapy against cancer, and are immunized with rod cells introduced with a gene encoding a tumor antigen or T cells stimulated with the rod cells. Is an effective way to induce anti-tumor effects in patients.
- the present invention relates to the use of rod-shaped cells obtained by the method of the present invention in anticancer therapy.
- the present invention also relates to the use of the rod-shaped cells obtained by the method of the present invention in the production of an anticancer agent (or anticancer agent, cancer growth inhibitor, etc.).
- the present invention also relates to the use of RNA viruses and rod cells in the production of anticancer agents (or anticancer agents, cancer growth inhibitors, etc.).
- the obtained rod-shaped cells are useful as a DC vaccine.
- To increase immunogenicity To increase immunogenicity,
- an immunostimulant such as cyto force-in, cholera toxin, salmonella toxin, etc.
- an immunostimulant such as cyto force-in, cholera toxin, salmonella toxin, etc.
- aschnunts such as alum, imperfect Freund's adjuvant, MF59 (oil emulsion), MTP-PE (muramyl tripeptide derived from mycobacterial cell wall), and QS-21 (derived from soapbark tree Quilaia saponaria).
- the present invention also relates to a package comprising an RNA virus and a rod-shaped cell, comprising a description of using the rod-shaped cell for cancer suppression.
- the RNA virus and the dendritic cell may be contained in separate containers or in the same container.
- the present invention also relates to a package containing rod cells into which an RNA virus has been introduced, the package including a description of using the rod cells for cancer suppression.
- RNA virus and rod cells can be suspended in a solution such as a culture solution or physiological saline.
- a rod-like cell into which an RNA virus has been introduced or a composition containing the same is used for tumor suppression, such as tumor growth suppression, cancer degeneration, cancer therapy, treatment of cancer patients' treatment, survival of cancer patients Or used as an anticancer agent.
- the description should be directly on the cage / cage.
- the package may include a paper or a seal including the description.
- the knock container is a container containing RNA virus and / or rod-like cells, and in this case, the container may be, for example, a bottle, a tube, a plastic bag, a vial, a syringe, or the like.
- the knocker of the present invention may include a bag or an outer box for storing the container.
- the package may further include a syringe, a catheter, and / or an injection needle for the administration of the rod cells, which may include instructions describing how to administer the rod cells.
- the anticancer agent produced by the present invention is inoculated into the body, it is safer if the rod-shaped cells contained therein are eliminated from cell proliferation.
- umbilical cord blood-derived monocytes are known to have an extremely low proliferation ability by induction of differentiation.
- heat treatment, radiation treatment, or It can be treated with mitomycin C treatment, etc., and the growth can be lost while retaining the function as a vaccine.
- irradiation can be performed with a total radiation dose of 1000 to 3300 Rad.
- mitomycin C treatment method for example, 25-50 micro-g / ml mitomycin C can be added to rod cells and incubated at 37 ° C for 30-60 minutes.
- heat treatment can be performed at 50 to 65 ° C. for 20 minutes.
- cyto-forces that enhance the adjuvant effect.
- genes include i) a combination of IL-2 and single-stranded IL-12 (Proc. Natl. Acad. Sci. USA 96 (15): 8591-8596, 1999), ii) IL-2 And interferon- ⁇ (US Pat. No. 5,798,100), iii) Granulocyte colony stimulating factor (GM-CSF) used alone, iv) Combination of GM-CSF and IL-4 (J. Neurosurgery 90 (6 ), 1115-1124 (1999)).
- the rod cells transfected with the RNA virus are useful for stimulating the patient's own T cells in vivo, or the rod cells are also useful for stimulating the T cells in vitro. is there .
- Sensitized T cells are administered to the patient and stimulate the patient's tumor immunity via etha vivo immunotherapy.
- the present invention relates to a method for producing an anticancer agent comprising a T cell stimulated by a rod-shaped cell, comprising: (a) a step of introducing an RNA virus into the rod-shaped cell or a progenitor cell thereof; (b) the cell; Mature And (c) presenting a cancer antigen to the mature rod cells, and (d) contacting the mature rod cells with a T cell.
- a rod-shaped cell into which an RNA virus has been introduced activates T cells and induces CTL.
- the antigen presented in the rod cells may be a cancer antigen (or processed product thereof) that also expresses RNA viral power, or may be pulsed into external force rod cells.
- the obtained T cells can be used for cancer treatment. When contacting T cells and rod cells in vitro, it is preferable to collect T cells from a patient and contact them with rod cells, and then administer the T cells in vivo.
- the present invention also relates to a method for suppressing cancer using the rod-shaped cells produced by the method of the present invention.
- treatments that stimulate anti-tumor immunity in cancer patients can be performed.
- This method is a method including the step of administering rod-shaped cells.
- the method includes a step of administering to a patient a therapeutically effective amount of a rod-shaped cell having an RNP complex of an RNA virus having genome replication ability.
- This method can be expected to suppress the growth of cancer compared to the case where the rod-shaped cells of the present invention are not administered.
- RNA viruses may have no foreign genes or have genes that encode one or more of cancer antigens, immunostimulatory site force-in, proteins that inhibit angiogenesis, etc. Also good.
- RNA viruses When RNA viruses are introduced into rod cells, the rod cells become active. Therefore, administration of rod cells that do not have foreign genes and have RNA viruses introduced into cancer can also be used by patients with cancer.
- the immune system can be activated. By pulsing a cancer antigen peptide in these rod-shaped cells to present a desired antigen, rod-shaped cells with a further enhanced cancer suppression effect can be obtained.
- the present invention can be applied to a desired solid cancer such as tongue cancer, gingival cancer, malignant lymphoma, malignant melanoma, maxillary cancer, nasal cancer, nasal cavity cancer, laryngeal cancer, pharyngeal cancer.
- a desired solid cancer such as tongue cancer, gingival cancer, malignant lymphoma, malignant melanoma, maxillary cancer, nasal cancer, nasal cavity cancer, laryngeal cancer, pharyngeal cancer.
- Glioma meningioma, glioma, lung cancer, breast cancer, spleen cancer, gastrointestinal cancer (esophageal cancer, stomach cancer, duodenal cancer, colon cancer), squamous cell carcinoma, adenocarcinoma, alveolar epithelial cancer, testicular tumor Prostate cancer, thyroid cancer, liver cancer, ovarian cancer, rhabdomyosarcoma, fibrosarcoma, osteosarcoma, chondrosarcoma and the like.
- the target cancer is preferably epithelial cancer, more preferably skin cancer including cutaneous squamous cell carcinoma, cutaneous basal cell carcinoma, cutaneous Paget's disease, cutaneous Paget's disease, cutaneous malignant melanoma and the like.
- RNA virus When administering rod-like cells into which an RNA virus has been introduced, generally 10 5 to 10 9 cells, preferably Preferably 10 6 to 10 8 cells, more preferably about 10 7 cells are administered to the patient's cancer lesion.
- a cancer lesion refers to a cancer tissue or a region around it (for example, within 5 mm, preferably within 3 mm from cancer). Dosage should be adjusted appropriately depending on the type and stage of cancer and the presence or absence of the transgene.
- An RNA virus can be expected to have an antitumor effect even if it does not carry a foreign gene, but a higher effect can be obtained by loading an IFN-beta gene or a soluble FGF receptor gene into the RNA virus.
- Tumor antigens can be contacted with rod cells by mixing rod cells and cell lysate of tumor cells, pulsing tumor antigen peptide to rod cells, or rod cells.
- a method of introducing and expressing a tumor antigen gene can be used.
- An antitumor effect can also be obtained by directly injecting a desired vector carrying IFN-beta, a soluble FGF receptor, or a gene encoding them into the cancer lesion together with the cells of the present invention. That is, the combination of administration of rod cells into which RNA virus has been introduced and antitumor treatment with IFN-beta or soluble FGF receptor is suitable for the present invention.
- the T cells activated I spoon by ⁇ cells such as T cells
- about 105 to 109 cells per 1 m 2 body surface area preferably 10 6 to 10 9 cells
- the infusion can be repeated at a desired interval (eg, monthly).
- Post-dose recipients may be monitored during or after T cell infusion for any side effects as needed.
- the T cells have the same patient power as the patient who obtained the rod-shaped cells.
- the rod-shaped cells used to collect T-cell power and stimulate T cells may be derived from an HLA-compatible healthy donor.
- rod cells are taken from the patient, and the T cells can be derived from an HLA-compatible healthy donor!
- the number of administration of the rod cells or T cells can be one time or multiple times within the range of clinically acceptable side effects, and the same applies to the number of daily administration.
- the administration target is not particularly limited, but for example, birds, mammals (humans, including chickens, quails, mice, rats, dogs, pigs, cats, rabbits, magpies, hidges, goats, monkeys, and humans) And non-human mammals).
- mammals humans, including chickens, quails, mice, rats, dogs, pigs, cats, rabbits, magpies, hidges, goats, monkeys, and humans
- the weight of the target animal and human An amount converted from the above dose can be administered in a ratio.
- Monocytes were enriched by negative selection from healthy individuals.
- tetrameric antibody an antibody to which two antibody molecules are bound, one of which is an anti-glycophorin A antibody that recognizes erythrocytes and the other is an antibody that recognizes mononuclear cell surface antigens
- the cells were bound to erythrocytes and removed by Ficoll Paque TM Plus (Pharmacia Biotech Inc.). By this negative selection, cells expressing CD2, CD3, CD8, CD19, CD56, and CD66b were removed, and the remaining cells were used as monocyte-enriched cells for subsequent differentiation induction of DC. At this time, CD14 + cells were 65-80%.
- DCs were prepared after adding GM-CSF (500 U / ml) and IL-4 (250 U / ml) to monocyte-enriched cells and culturing with endotoxin free RPMI + 10% FCS. On day 3-4, half of the culture supernatant was replaced with a new culture medium having the same composition. Confirm positive expression of costimulatory molecules, CDl lc, HLA-class II (DR, DP, DQ), and CDla, and other lineage markers (CD3, CD56, CD19, CD15 and It was also confirmed that CD14) was not expressed ( Figure 1 and data not shown). Using these cells, virus introduction efficiency was examined. At this time, 90-98% of living cells expressed DC markers (CDllc, HLA-class II (DR, DP, DQ).
- DCs were infected with SeV-GFP at MOI 20, and GFP expression was examined over time using FACS. As a result, although the expression decreased after 2 weeks (the number of cells also decreased), the expressed cells could be confirmed up to 2 months (Fig. 7). As shown in the examples below, DC is activated upon infection with RNA viruses. Therefore, gene transfer into DC using RNA virus can be applied to vaccines as a clinical application. Administration can be performed in vivo or ET vivo, but, for example, by frequent administration of DC infected with RNA virus by ET vivo, gene expression in the body can be sustained over a long period of time.
- CD34 positive stem cells were isolated from human umbilical cord blood using CD34 microbeads (CD34> 90%), infected with MOI 0, 10, 100, and then washed well. The cells were added to RPMI + 10% FCS with SCF (50 ng / ml), GM-CSF (500 U / ml), TNF—alpha (50 ng / ml), cultured for 3 days, and then SCF (50 ng / ml).
- RNA viruses are much more efficient than lentiviruses and retroviruses, and it is very easy and quick to obtain introduction efficiencies that are not inferior to adenoviruses. It has been demonstrated that it can be done.
- the active marker does not change in other vectors! However, it was found that the activity of DC can be induced by RNA virus infection.
- DCs were infected with SeV-GFP at MOI 30-50 and stimulated with LPS one day later (2 days), and then the expression of costimulatory molecules was examined.
- comparative tests B and J were conducted for the conditions of LPS stimulation alone, SeV-GFP infection alone, and LPS stimulation and no SeV-GFP infection.
- DCs were infected with SeV-GFP at MOI 30 (3 days after infection, 1 day after infection, one group was stimulated with LPS), and the phagocytic ability of the same group as in Experiment 1 was examined (1 micron) -m PCV-RED latex- microspheres (bar graph minus the positive background at 4 ° C).
- monocyte-derived rod-shaped cells obtained from 7-day culture were cultured in a 12-well plate. 48 hours (8xl0 5 / 2ml / well: medium is X-vivol5 TM + 2% autologous serum + GM-CSF (500 U / ml) + IL-4 (250 U / ml)), cultured under the conditions of the following groups The TNF-alpha, IL-lbeta, IL-6, and IL-8 values in the supernatant were measured with the Luminex TM system. SeV infection was cultured at MOI 30 for 2 days.
- Allantoic fluid group Chicken egg urine fluid, which is a suspension of SeV (excluding SeV) 60 micro-L added group
- UV-SeV-GFP group A solution obtained by removing the replication ability by irradiating the SeV-GFP solution with ultraviolet rays.
- SeV-GFP A group with 60 microL added SeV-GFP solution (replication-competent SeV) Result: Without UV irradiation, GFP was introduced into a replicable SeV (replication-competent SeV) Only rod cells produced TNF-alpha, IL-lbeta, IL-6, increased IL-8 production ( Figure 18). At this time, CD40, CD80, CD83, CD86, and HLA-DR increased expression on the rod-shaped cells were induced only by replication-competent SeV (FIGS. 19 and 20). This means that only the gene transfer of SeV into rod cells can induce the production of proinflammatory cytokines, which are important during immune responses, by rod cells.
- the same experimental group as above was irradiated with 3000 rad of DC, and then the T cells were activated. I examined my ability! (DC co-cultured with dose and co-cultured for 3 days with Aro or syngenic T cells purified (CD3 +> 95%)). Syngenic T cells were used as an indicator of the response to SeV-GFP.
- RNA virus Human monocyte-derived ⁇ cells obtained in 7 days of culture the (MoDCs) for 48 hours at Plate 12 Ueru ⁇ 1 X 10 6/2 ml / well: medium is X-vivol5 TM + 2% Self Serum + GM-CSF (500 U / ml) + IL-4 (250 U / ml), cultured under the conditions of the following groups: As an RNA virus, the F gene is deleted, the temperature-sensitive mutation M and the HN protein (M gene: G69E, T116A, A183S, HN gene: A262T, G264R, K461G) are loaded, and the persistent infection type Comparison of Sendai virus (SeV-dFM ts HN ts PLmut-GFP (also abbreviated as Se
- SeV (-) group Medium only group
- SeV-dFM ts HN ts PLmut-GFP group SeV-dFM ts HN ts PLmut-GFP (F gene deficient with GFP, M / HN / P / L mutant SeV) was added at MOI 50 group
- SeV-GFP group A group of SeV-GFP (propagation type SeV loaded with GFP) added at MOI 50 'Site force in cocktail group: Site force in cocktail group (IL-1 ⁇ 50 ng / ml) , IL-6 500 ng / ml, INF-a 2500 U / ml, TNF—a 100 ng / ml, PGE 20 ⁇ M)
- the MoDC obtained was irradiated with 30 Gy, and then the MoDC (4 x 10 to 6.25 x 10 2 / well) and peripheral blood T cells from the mouth (1 x 10 5 / well) From the peripheral blood, T cells with a purity of 96% or higher obtained using the RosetteSep-human T cell enrichment kit (StemCell Technologies, Vancouver, Canada) were cultured for 4 days, and 1 ⁇ Ci of [ 3 H] - thymidine was ⁇ Ka ⁇ and after 8 hours [] - uptake of thymidine a Beta Plate system (Pahrmacia LKB Biothechnology, Uppsala, Sweden;.
- CD14 + cells from human peripheral blood HLA-A 0201 healthy donor
- GM—CSF 500U
- TM Membrex
- IL-4 250 U / ml
- the cells were cultured in the presence of GM-CSF (500 U / ml) and IL-4 (250 U / ml). 1 group Add nothing
- the rod cells were collected and pulsed with MART-1 peptide (EAAGIGILTV (SEQ ID NO: 1) (50 micro-g / ml; 3 hours), and the same healthy human peripheral where the rod cells were collected.
- Blood T cells were enriched by negative selection (CD3 +> 97%) and cultured for 7 days with the above 3 groups of rod-shaped cells pulsed with peptides (X- vivo 15 TM + 2% autologous serum) (3-4). Half of the medium was changed every day or when the medium turned yellow.At the first stimulation, T cells and rod cells were mixed and cultured without IL-2, and IL-2 was added at 100 U / ml from the third day. This was repeated twice, and cells were collected from each mixed culture and used as effector cells in the CTL assay.
- EAAGIGILTV SEQ ID NO: 1
- the target cells used were T2 cells (T cell-B cell hybridoma obtained from HLA-A2 + humans and a TAP-deficient cell line). Since these cells do not have TAP (transporter to class I), peptides produced by the degradation of cytoplasmic proteins cannot be induced to Class I. When peptides are added from outside, the peptides become Class I. When loaded, Class I expression occurs.
- This target was pulsed with a mutated MART-1 peptide (ELAGIGILTV (SEQ ID NO: 2)) (in which the T cell receptor recognition part does not change with respect to the peptide used in the above stimulation, and the binding of HLA-A2 is enhanced) ,
- ELAGIGILTV SEQ ID NO: 2
- a peptide of Infoluenza Flu; a peptide as a third party; GILGFVFTL (SEQ ID NO: 3)
- CTL activity was examined by mixing and culturing at 1, 10: 1, 5: 1, 2.5: 1 for 4 hours.
- This example shows an example of a method for treating tumors by in vivo and etha vivo administration of RNA virus.
- Tumor model mice were C57BL / 6 mice (6-8 weeks old, female) (Nippon Charles 'Liver), and rod cells were C57BL / 6 mice (8 weeks old, female) (Nippon Charles' Liver). From 1). Spider cells were collected from the thigh of C57BL / 6 mice, and SpinSep, murine hematopoetic progenitor
- rod cells without activation stimulation rod cells activated with LPS (LPS DC), or SeV-IFN ⁇ expressing SeV-GFP or mouse interferon 13
- LPS LPS
- the rod-shaped cells (SeV GFP DC or SeV IFN
- a tumor antigen tumor lysate by freeze and thaw of B 16 was pulsed and administered to rod cells.
- an experiment was conducted to examine the antitumor effect by direct intratumoral injection of SeV-IFN j8 on the 10th day after tumor inoculation (day 10).
- the rod cells cultured for 1 week as described above were infected with SeV-IFN ⁇ at 40 ° C. and cultured for 8 hours.
- SeV-IFN j8 was infected with MOI 40 and cultured for 8 hours. Thereafter, these rod-shaped cells were collected and 5xl0 5 to 5 ⁇ 5 cells were administered around the tumor of the mouse.
- spleens were extracted from mice 7 days after the completion of 3 DC treatments for each treatment group, and effector cells were prepared. As a target
- Yac-1 was used for 51 Cr release.
- the remaining spleen cells used in the above NK cell activity assay were used together with TRP-2 peptide, which is a tumor antigen of B16, and the cells cultured for 5 days as effectors
- the cells were used as cells and co-cultured with EL-4 target cells pulsed with mTRP-2 peptide and subjected to 51 Cr release assay.
- the percentage of specific 51 Cr release was calculated as follows:
- SeV human soluble FGF receptor
- SeV-hsPDGFR Sendai virus expressing human soluble FGF receptor
- the tumor size was significantly reduced in all SeV administration groups compared to the SeV non-administration group (Fig. 27).
- the tumor growth inhibitory effect was confirmed to be stronger than when administered with SeV-GFP, and antitumor effect when administered with SeV expressing soluble PDGFR a was the most prominent, and the tumor size was almost increasing.
- Sendai virus (GFP expressing SeV; SeV-GFP) without MOI 60 or Sendai virus (SeV-hsPDGFR a) expressing human soluble PDGF ⁇ receptor, tumor antigen Genes were introduced by infecting Sendai virus (SeV-TRP2) expressing TRP2 or Sendai virus (SeV-gplOO) expressing tumor antigen gplOO with MOI 20 each.
- FIG. 28 shows the results of intratumoral injection of 1 ⁇ 10 6 rod-shaped cells into which SeV-hsPDGFRa was introduced, and thereafter measuring the tumor size over time. Similar to the in vivo administration of the virus described above, the tumor size was significantly reduced in the mice administered with the rod cells transfected with SeV-GFP as compared with the mice administered with the rod cells not transfected with SeV. The anti-tumor effect of SeV was more pronounced than that of in vivo administration of SeV using rodent cells (Fig. 28). Administration of rodent cells treated with SeV expressing soluble PDGFR a further increased the anti-tumor effect and increased the tumor size.
- an anticancer agent comprising a rod-shaped cell into which an RNA virus has been introduced as an active ingredient is provided. Since the introduction of RNA virus induces the activity of rod cells, it is possible to omit the activity treatment process such as site force-in after introduction, maintaining cell viability, reducing costs, and further ex vivo. This is considered to contribute to the reduction of the operation time.
- the present invention enables new viral therapies that combine RNA viruses and rod-shaped cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006528384A JP5296983B2 (ja) | 2004-06-24 | 2005-04-28 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
CN2005800284040A CN101006172B (zh) | 2004-06-24 | 2005-04-28 | 包含导入了rna病毒的树突状细胞的抗癌剂 |
CA002571849A CA2571849A1 (en) | 2004-06-24 | 2005-04-28 | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
AU2005257107A AU2005257107A1 (en) | 2004-06-24 | 2005-04-28 | Anticancer agent containing dendritic cell having RNA virus transferred thereinto |
KR1020077001606A KR101270839B1 (ko) | 2004-06-24 | 2005-04-28 | Rna 바이러스가 도입된 수상세포를 포함하는 항암제 |
US11/630,532 US8889118B2 (en) | 2004-06-24 | 2005-04-28 | Anticancer agent containing dendritic cell having RNA virus transferred thereinto |
EP05737340A EP1775343A4 (en) | 2004-06-24 | 2005-04-28 | ANTICANCER AGENTS CONTAINING A DENDRITIC CELL IN WHICH RNA VIRUSES HAVE BEEN TRANSFERRED |
HK08100566.6A HK1106794A1 (en) | 2004-06-24 | 2008-01-16 | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004187028 | 2004-06-24 | ||
JP2004-187028 | 2004-06-24 | ||
JPPCT/JP2004/016089 | 2004-10-29 | ||
PCT/JP2004/016089 WO2005042737A1 (ja) | 2003-11-04 | 2004-10-29 | 遺伝子導入された樹状細胞の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006001122A1 true WO2006001122A1 (ja) | 2006-01-05 |
Family
ID=37866022
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008175 WO2006001122A1 (ja) | 2004-06-24 | 2005-04-28 | Rnaウイルスが導入された樹状細胞を含む抗癌剤 |
PCT/JP2005/008124 WO2006001120A1 (ja) | 2004-06-24 | 2005-04-28 | マイナス鎖rnaウイルスを含む抗癌剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008124 WO2006001120A1 (ja) | 2004-06-24 | 2005-04-28 | マイナス鎖rnaウイルスを含む抗癌剤 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8889118B2 (ja) |
EP (2) | EP1775342A4 (ja) |
JP (3) | JPWO2006001120A1 (ja) |
KR (2) | KR20070028573A (ja) |
CN (2) | CN101006172B (ja) |
AU (2) | AU2005257107A1 (ja) |
CA (2) | CA2571849A1 (ja) |
HK (1) | HK1106794A1 (ja) |
WO (2) | WO2006001122A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008065752A1 (fr) * | 2006-11-30 | 2008-06-05 | National University Corporation Hokkaido University | Agent immunothérapeutique contenant un arndi en tant que principe actif |
WO2010055900A1 (ja) | 2008-11-14 | 2010-05-20 | ディナベック株式会社 | 樹状細胞の製造方法 |
US8283163B2 (en) | 2007-05-17 | 2012-10-09 | Dnavec Corporation | Method for production of dendritic cell |
JP2019522481A (ja) * | 2016-06-22 | 2019-08-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 自己切断リボザイムを利用したrnaのウイルス送達およびそのcrisprベースの適用 |
JP2022023061A (ja) * | 2015-09-26 | 2022-02-07 | プライムヴァックス イミュノ-オンコロジー,インク. | 樹状細胞を産生するための組成物及び方法 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69638196D1 (de) * | 1995-11-01 | 2010-07-22 | Dnavec Research Inc | Rekombinantes sendai-virus |
US20030166252A1 (en) * | 1999-05-18 | 2003-09-04 | Kaio Kitazato | Paramyxovirus-derived RNP |
US20020002143A1 (en) * | 2000-03-30 | 2002-01-03 | Munehide Kano | AIDS virus vaccines using sendai virus vector |
US20060104950A1 (en) * | 2002-10-24 | 2006-05-18 | Shinji Okano | Methods of Tranducing genes into T cells |
KR101279748B1 (ko) * | 2003-11-04 | 2013-07-04 | 가부시키가이샤 디나벡크 겐큐쇼 | 유전자 도입된 수상세포의 제조방법 |
EP1712243A4 (en) * | 2004-01-13 | 2007-04-11 | Dnavec Research Inc | GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE |
AU2005206410A1 (en) * | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter |
WO2005097988A1 (ja) * | 2004-03-23 | 2005-10-20 | Dnavec Research Inc. | 組織の維持および/または修復に関連する骨髄関連細胞 |
CA2571849A1 (en) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
EP1916298B1 (en) * | 2005-06-14 | 2011-12-28 | Dnavec Corporation | Methods for producing monoclonal antibodies |
CN101405389A (zh) * | 2006-01-17 | 2009-04-08 | 生物载体株式会社 | 新型蛋白质表达系统 |
US20090053790A1 (en) * | 2006-01-31 | 2009-02-26 | Ishihara Sangyo Kaisha, Ltd. | Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell |
KR20140146224A (ko) | 2006-04-14 | 2014-12-24 | 어드밴스드 셀 테크놀로지, 인코포레이티드 | 혈관 콜로니 형성 세포 |
EP2952583A1 (en) | 2007-03-12 | 2015-12-09 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
JPWO2008136438A1 (ja) * | 2007-04-27 | 2010-07-29 | 国立大学法人九州大学 | 遺伝子治療用ウイルスベクター |
US8719420B2 (en) * | 2008-05-13 | 2014-05-06 | At&T Mobility Ii Llc | Administration of access lists for femtocell service |
US8691212B2 (en) * | 2008-09-16 | 2014-04-08 | Genomldea Inc. | Therapeutic/prophylactic agent for prostate cancer |
US20100266642A1 (en) * | 2009-02-20 | 2010-10-21 | Bind Biosciences, Inc. | Modified cells for targeted cell trafficking and uses thereof |
EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
JP6013187B2 (ja) * | 2009-12-04 | 2016-10-25 | ステム セル アンド リジェネレイティブ メディスン インターナショナル, インコーポレイテッド | ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法 |
DE102010018961B4 (de) * | 2010-04-23 | 2012-09-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen |
KR101365208B1 (ko) * | 2011-12-06 | 2014-02-20 | 가톨릭대학교 산학협력단 | 바이러스를 이용하여 제조된 심근염 치료용 면역관용 수지상 세포 및 이의 제조 방법 |
CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
CA2991212A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
CN110139671A (zh) | 2016-11-16 | 2019-08-16 | 普莱瓦克斯免疫肿瘤学公司 | 用于治疗癌症的组合免疫疗法 |
CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000070070A1 (fr) * | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe |
JP2002272465A (ja) * | 2000-05-18 | 2002-09-24 | Dnavec Research Inc | 外来遺伝子導入用パラミクソウイルスベクター |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124148A (en) * | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
PT1314431E (pt) * | 1993-04-30 | 2008-10-24 | Wellstat Biologics Corp | Composições purificadas de vírus da doença de newcastle |
US6300090B1 (en) * | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
EP0864645B9 (en) * | 1995-10-31 | 2006-03-22 | Dnavec Research Inc. | Negative-strand rna virus vector having autonomously replicating activity |
DE69638196D1 (de) * | 1995-11-01 | 2010-07-22 | Dnavec Research Inc | Rekombinantes sendai-virus |
US6734014B1 (en) * | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
EP0941122B1 (en) | 1996-08-13 | 2003-10-29 | Chiron Corporation | Compositions for polynucleotide delivery |
WO1998053048A1 (en) * | 1997-05-21 | 1998-11-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells |
JP2000253876A (ja) | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
US20030022376A1 (en) * | 1999-05-18 | 2003-01-30 | Kaio Kitazato | Paramyxovirus-derived RNP |
US20030166252A1 (en) * | 1999-05-18 | 2003-09-04 | Kaio Kitazato | Paramyxovirus-derived RNP |
US20020169306A1 (en) * | 1999-05-18 | 2002-11-14 | Kaio Kitazato | Envelope gene-deficient paramyxovirus vector |
EP1179594B1 (en) | 1999-05-18 | 2008-06-25 | Dnavec Research Inc. | Ribonucleoprotein complex in paramyxovirus |
US7226786B2 (en) * | 1999-05-18 | 2007-06-05 | Dnavec Research Inc. | Envelope gene-deficient Paramyxovirus vector |
US20020123479A1 (en) * | 1999-12-08 | 2002-09-05 | Song Elizabeth S. | Immunostimulation mediated by gene-modified dendritic cells |
US6472208B1 (en) * | 1999-12-13 | 2002-10-29 | Héma-Québec | Method of producing human IFN-α using sendai virus-infected hematopoietic stem cells |
US20020002143A1 (en) * | 2000-03-30 | 2002-01-03 | Munehide Kano | AIDS virus vaccines using sendai virus vector |
CA2322057A1 (en) * | 2000-05-18 | 2001-11-18 | Dnavec Research Inc. | Paramyxovirus vectors used for transfer of foreign genes |
AU2002305452A1 (en) * | 2001-05-08 | 2002-11-18 | Emory University | Regulating immine responses using dendritic cells |
WO2003004616A2 (en) | 2001-07-05 | 2003-01-16 | Phylogix, Inc. | Dendritic cell isolation methods |
BRPI0212545B8 (pt) | 2001-09-06 | 2021-05-25 | Northwest Biotherapeutics Inc | método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t |
CN1633599A (zh) * | 2001-09-18 | 2005-06-29 | 株式会社载体研究所 | 检查和制造降低了粒子形成能力的(-)链rna载体的方法 |
EP1438399A4 (en) * | 2001-09-28 | 2005-09-14 | Univ North Carolina | PARAMYXOVIRUSES AS GENE TRANSFER VECTORS TO PULMONARY CELLS |
CN1596311A (zh) * | 2001-09-28 | 2005-03-16 | 株式会社载体研究所 | 编码表位结合型β2m且感染哺乳动物细胞的病毒载体及其应用 |
FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
WO2003102183A1 (fr) | 2002-06-03 | 2003-12-11 | Dnavec Research Inc. | Vecteurs de paramyxovirus codant pour un anticorps et son utilisation |
AU2002951082A0 (en) | 2002-08-30 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic cellular agents |
US20060104950A1 (en) * | 2002-10-24 | 2006-05-18 | Shinji Okano | Methods of Tranducing genes into T cells |
AU2003296439B2 (en) * | 2002-12-10 | 2009-05-07 | Argos Therapeutics, Inc. | In situ maturation of dendritic cells |
KR101279748B1 (ko) * | 2003-11-04 | 2013-07-04 | 가부시키가이샤 디나벡크 겐큐쇼 | 유전자 도입된 수상세포의 제조방법 |
EP1712243A4 (en) * | 2004-01-13 | 2007-04-11 | Dnavec Research Inc | GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE |
AU2005206410A1 (en) * | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter |
CN1934257A (zh) * | 2004-01-22 | 2007-03-21 | 株式会社载体研究所 | 病毒载体的制备方法 |
CA2560046A1 (en) * | 2004-03-16 | 2005-09-22 | Dnavec Research Inc. | Methods for suppressing tumor proliferation |
WO2005097988A1 (ja) * | 2004-03-23 | 2005-10-20 | Dnavec Research Inc. | 組織の維持および/または修復に関連する骨髄関連細胞 |
CA2571849A1 (en) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
KR20080031167A (ko) * | 2005-04-20 | 2008-04-08 | 디나벡크 가부시키가이샤 | 알츠하이머병 치료용의 고도로 안전한 비강투여용 유전자백신 |
CA2654033A1 (en) * | 2006-05-31 | 2007-12-06 | Dnavec Corporation | Therapeutic agent for alzheimer's disease |
JP5227317B2 (ja) * | 2007-05-17 | 2013-07-03 | ディナベック株式会社 | 樹状細胞の製造方法 |
-
2005
- 2005-04-28 CA CA002571849A patent/CA2571849A1/en not_active Abandoned
- 2005-04-28 AU AU2005257107A patent/AU2005257107A1/en not_active Abandoned
- 2005-04-28 KR KR1020077001605A patent/KR20070028573A/ko not_active Application Discontinuation
- 2005-04-28 US US11/630,532 patent/US8889118B2/en not_active Expired - Fee Related
- 2005-04-28 WO PCT/JP2005/008175 patent/WO2006001122A1/ja active Application Filing
- 2005-04-28 US US11/630,522 patent/US20080031855A1/en not_active Abandoned
- 2005-04-28 JP JP2006528383A patent/JPWO2006001120A1/ja not_active Withdrawn
- 2005-04-28 EP EP05736740A patent/EP1775342A4/en active Pending
- 2005-04-28 EP EP05737340A patent/EP1775343A4/en not_active Withdrawn
- 2005-04-28 CN CN2005800284040A patent/CN101006172B/zh not_active Expired - Fee Related
- 2005-04-28 AU AU2005257105A patent/AU2005257105A1/en not_active Abandoned
- 2005-04-28 WO PCT/JP2005/008124 patent/WO2006001120A1/ja active Application Filing
- 2005-04-28 CA CA002571844A patent/CA2571844A1/en not_active Abandoned
- 2005-04-28 CN CNA2005800284036A patent/CN101006171A/zh active Pending
- 2005-04-28 KR KR1020077001606A patent/KR101270839B1/ko not_active IP Right Cessation
- 2005-04-28 JP JP2006528384A patent/JP5296983B2/ja not_active Expired - Fee Related
-
2008
- 2008-01-16 HK HK08100566.6A patent/HK1106794A1/xx not_active IP Right Cessation
-
2013
- 2013-03-08 JP JP2013046159A patent/JP2013151523A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000070070A1 (fr) * | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe |
JP2002272465A (ja) * | 2000-05-18 | 2002-09-24 | Dnavec Research Inc | 外来遺伝子導入用パラミクソウイルスベクター |
Non-Patent Citations (6)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008065752A1 (fr) * | 2006-11-30 | 2008-06-05 | National University Corporation Hokkaido University | Agent immunothérapeutique contenant un arndi en tant que principe actif |
US8283163B2 (en) | 2007-05-17 | 2012-10-09 | Dnavec Corporation | Method for production of dendritic cell |
WO2010055900A1 (ja) | 2008-11-14 | 2010-05-20 | ディナベック株式会社 | 樹状細胞の製造方法 |
JP2022023061A (ja) * | 2015-09-26 | 2022-02-07 | プライムヴァックス イミュノ-オンコロジー,インク. | 樹状細胞を産生するための組成物及び方法 |
JP2019522481A (ja) * | 2016-06-22 | 2019-08-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 自己切断リボザイムを利用したrnaのウイルス送達およびそのcrisprベースの適用 |
Also Published As
Publication number | Publication date |
---|---|
AU2005257107A1 (en) | 2006-01-05 |
CN101006172B (zh) | 2012-09-05 |
EP1775343A1 (en) | 2007-04-18 |
US20080014183A1 (en) | 2008-01-17 |
EP1775342A4 (en) | 2007-11-07 |
JPWO2006001120A1 (ja) | 2008-04-17 |
EP1775343A8 (en) | 2007-09-26 |
JP2013151523A (ja) | 2013-08-08 |
CN101006171A (zh) | 2007-07-25 |
US20080031855A1 (en) | 2008-02-07 |
EP1775342A1 (en) | 2007-04-18 |
HK1106794A1 (en) | 2008-03-20 |
JPWO2006001122A1 (ja) | 2008-04-17 |
KR20070032022A (ko) | 2007-03-20 |
KR20070028573A (ko) | 2007-03-12 |
CN101006172A (zh) | 2007-07-25 |
AU2005257105A1 (en) | 2006-01-05 |
US8889118B2 (en) | 2014-11-18 |
CA2571844A1 (en) | 2006-01-05 |
CA2571849A1 (en) | 2006-01-05 |
EP1775342A8 (en) | 2007-06-20 |
JP5296983B2 (ja) | 2013-09-25 |
KR101270839B1 (ko) | 2013-06-05 |
EP1775343A4 (en) | 2007-11-14 |
WO2006001120A1 (ja) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5296983B2 (ja) | Rnaウイルスが導入された樹状細胞を含む抗癌剤 | |
JP2012065652A (ja) | 遺伝子導入された樹状細胞の製造方法 | |
KR101506751B1 (ko) | 수상세포의 제조방법 | |
JP6182175B2 (ja) | 樹状細胞の製造方法 | |
US20060165668A1 (en) | Genetically modified tumor cells as cancer vaccines | |
US9695444B2 (en) | Vaccine prepared utilizing human parainfluenza virus type 2 vector | |
EP1712243A1 (en) | Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines | |
WO2019183802A1 (zh) | 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用 | |
JPWO2008136438A1 (ja) | 遺伝子治療用ウイルスベクター |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006528384 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2571849 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005257107 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077001606 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005737340 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005257107 Country of ref document: AU Date of ref document: 20050428 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005257107 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580028404.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020077001606 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005737340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11630532 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11630532 Country of ref document: US |